NanoPin Technologies

Executive Summary

NanoPin Technologies is a private biotechnology company headquartered in San Diego, California, focused on developing novel nanotechnology-based diagnostic platforms for infectious diseases. Founded in 2017, the company’s proprietary assays aim to provide rapid, accurate detection of active disease from blood samples, with an initial emphasis on tuberculosis (TB), HIV, and COVID-19. A key differentiator of NanoPin’s technology is its ability to distinguish between latent and active infection, a critical need in TB management, and to function effectively across diverse patient populations, including children and immunocompromised individuals. The company’s platform leverages nanotechnology to potentially improve sensitivity and reduce time-to-result compared to existing diagnostic methods. The global diagnostic market for infectious diseases is substantial, and NanoPin addresses significant unmet needs, particularly in TB where sputum-based tests often fail in vulnerable groups. If validated, the company’s blood-based approach could streamline diagnosis, reduce transmission, and enable earlier treatment. NanoPin is currently in the clinical validation phase, with no disclosed funding or partnering details. The company’s ultimate success hinges on achieving regulatory clearances, demonstrating clinical utility in large studies, and securing commercial partnerships. With a focused pipeline and a differentiated technology, NanoPin represents a promising but early-stage opportunity in the diagnostics space.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) submission for TB diagnostic test70% success
• Q3 2026Publication of clinical validation data in peer-reviewed journal80% success
• Q2 2026Strategic partnership with global health organization or diagnostics company60% success